Efficacy and Safety Evaluation of iNstroke 5F Aspiration Catheter for Thrombectomy (iNFLOW-5)
Prospective, Single-arm, Multi-centre Study to Evaluate the Efficacy and Safety of the Instroke 5F Thromboaspiration Catheter in Patients With Acute Ischaemic Stroke.
Prospective, single-arm, multi-centre study to evaluate the efficacy and safety of the iNstroke 5F thromboaspiration catheter in patients with acute ischaemic stroke
調査の概要
詳細な説明
This clinical investigation has been designed to evaluate the efficacy and safety of the iNstroke 5F aspiration catheter for its use in the treatment of LVO, with a view to comparing this product with standard therapy or with other similar products in a future pivotal clinical investigation.
研究の種類
入学 (推定)
段階
- 適用できない
連絡先と場所
研究場所
-
-
Andalusia
-
Málaga、Andalusia、スペイン
- Hospital Regional Universitario de Málaga Carlos Haya
-
コンタクト:
- María Teresa Díaz, Dr.
- 電話番号:+34 936724711
- メール:clinica@ivascular.global
-
主任研究者:
- María Teresa Díaz, Dr.
-
-
Aragon
-
Zaragoza、Aragon、スペイン
- Hospital Universitario Miguel Servet
-
コンタクト:
- María Rosa Barrena
- 電話番号:+34 936724711
- メール:clinica@ivascular.global
-
主任研究者:
- María Rosa Barrena, Dr.
-
-
Barcelona
-
Barcelona、Barcelona、スペイン
- Hospital Clínico de Barcelona
-
コンタクト:
- Jordi Blasco, Dr
- 電話番号:+34 936724711
- メール:clinica@ivascular.global
-
主任研究者:
- Jordi Blasco, Dr.
-
-
Catalonia
-
L'Hospitalet de Llobregat、Catalonia、スペイン
- Hospital Universitario Bellvitge
-
-
Galicia
-
Vigo、Galicia、スペイン
- Hospital Álvaro Cunqueiro
-
コンタクト:
- Carlos Manuel Rodriguez, Dr.
- 電話番号:+34 936724711
- メール:clinica@ivascular.global
-
主任研究者:
- Carlos Manuel Rodriguez, Dr.
-
-
-
-
-
Bordeaux、フランス
- CHU Bordeaux (H Pellegrin)
-
主任研究者:
- Xavier Barreau, Dr.
-
コンタクト:
- Xavier Barreau, Dr
- 電話番号:+34 936724711
- メール:clinica@ivascular.global
-
Lille、フランス
- CHU Lille
-
コンタクト:
- Nicolas Bricout
- 電話番号:+34 936724711
- メール:clinica@ivascular.global
-
主任研究者:
- Nicolas Bricout, Dr.
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Subjects aged ≥ 18 years.
- Subjects able to be treated (i.e., defined by groin puncture time) within 24 hours of symptom onset or last time seen well.
- Occlusion in a large or proximal medium vessel (M1, proximal M2, A2 or P2) identified by magnetic resonance angiography (MRA) or computed tomography angiography (CTA).
- Baseline NIHSS score ≥ 6 assessed before the procedure.
- Pre-stroke mRS score ≤ 2.
- Subjects with an ASPECTS score ≥ 6.
- Informed consent obtained in accordance with the applicable country-specific regulations and as approved by the Ethics Committee (EC).
- France-specific inclusion criteria: As applicable under French law, subjects affiliated with a health social security scheme or equivalent.
Exclusion Criteria:
- Severe comorbidity and/or shortened life expectancy that will likely prevent improvement or follow up or that will render the procedure unlikely to benefit the patient.
- Severe allergy to contrast media.
- Women of child-bearing potential.
- Subjects with intracranial atherosclerotic occlusive disease or extra- or intracranial dissection.
- Medical history of thrombocytopenia (Platelets <100,000).
- Subjects with tandem occlusions (evidence of complete occlusion, high-grade stenosis or arterial dissection in the extracranial or petrous segment of the internal carotid artery).
- Subjects with occlusions in multiple vessels.
- Subjects with cancer who have a life expectancy of less than 6 months.
- Pre-existing neurological or psychiatric illness that could confound the neurological or functional assessments.
- Severe sustained hypertension (systolic pressure >185 mm Hg or diastolic pressure >110 mm Hg). Note: If blood pressure can be successfully reduced and maintained at an acceptable level by administering the medication recommended by the ESO (European Stroke Organisation) in its guidelines (also IV infusion of antihypertensives), the subject may be included.
- Known or suspected cerebral vasculitis.
- Known renal insufficiency with creatinine ≥3 mg/dl or Glomerular Filtration Rate (GFR) <30 mL/min.
- Current participation in an interventional drug or device study that may confound the results of this study.
- Intracranial stenosis proximal to the occlusion.
- France-specific exclusion criteria: As applicable under French law, breastfeeding women, persons deprived of their liberty by a judicial or administrative decision, or persons of legal age who are the subject of a legal protection measure.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
他の:Thromboaspiration using iNstroke 5F aspiration catheter
No comparator will be used as this is a traditional feasibility clinical investigation. The objective is to capture preliminary clinical performance, effectiveness and safety information to adequately plan an appropriate pivotal clinical investigation. |
Patients to undergo thromboaspiration with iNstroke 5F |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Recanalization Rate
時間枠:Intra-procedure
|
Recanalization rate with mTICI ≥2b in ≤3 revascularization passes using iNstroke Thrombus Extraction Aspiration Device aspiration catheter alone, or in conjunction with Stent Retriever |
Intra-procedure
|
協力者と研究者
スポンサー
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。